Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Intangibles (2016 - 2025)

CytomX Therapeutics' Intangibles history spans 12 years, with the latest figure at $438000.0 for Q4 2025.

  • For Q4 2025, Intangibles fell 24.87% year-over-year to $438000.0; the TTM value through Dec 2025 reached $438000.0, down 24.87%, while the annual FY2025 figure was $438000.0, 24.87% down from the prior year.
  • Intangibles reached $438000.0 in Q4 2025 per CTMX's latest filing, down from $474000.0 in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $1.1 million in Q1 2021 to a low of $438000.0 in Q4 2025.
  • Average Intangibles over 5 years is $783850.0, with a median of $784000.0 recorded in 2023.
  • Peak YoY movement for Intangibles: fell 11.44% in 2021, then decreased 24.87% in 2025.
  • A 5-year view of Intangibles shows it stood at $1.0 million in 2021, then decreased by 14.3% to $875000.0 in 2022, then fell by 16.69% to $729000.0 in 2023, then decreased by 20.03% to $583000.0 in 2024, then fell by 24.87% to $438000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Intangibles are $438000.0 (Q4 2025), $474000.0 (Q3 2025), and $510000.0 (Q2 2025).